Severity of corneal neovascularization may be reduced with topical ranibizumab
Corneal neovascularization may be treated with topical ranibizumab to reduce severity through decrease in the vessel caliber, according to a study.
The prospective, open-label, monocentric, uncontrolled, noncomparative study included 10 eyes of nine patients with corneal neovascularization. Lucentis (ranibizumab, Genentech) was administered 4 times a day for 3 weeks with a follow-up of 16 weeks. Measurements were taken for neovascular area, vessel caliber, area occupied by the corneal neovessels, mean diameter of the corneal neovessels and invasion area.
There was a significant decrease in neovascular area (55.3%, P < .001) for the entire follow-up period, and vessel caliber improved out to week 16 (59%, P < .001).
Disclosure: Giulio Ferrari, MD, has received a grant from the Bietti Eye Foundation. Reza Dana, MD, MSc, MPH, received financial support from Genentech and NIH EY-019098. The other authors have no financial or conflicts of interest to disclose.